37results about "Phosphorous compound active ingredients" patented technology

The present application provides a VVN001-containing ophthalmic composition comprising an active material selected from a sodium salt represented by formula I and / or a free acid thereof, and ophthalmic excipients, to reduce the ocular inflammatory response by inhibiting a T cell-mediated inflammatory response through the active material. The concentration of the buffering agent in current invention is very low and the final buffer capacity of this ophthalmic composition is very close to the buffering capacity of the tear, which is tear-friendly and comfortable, and to increase the average residence time of the active material of the present application, as well as to increase the bioavailability of the active material represented by formula I according to the present application.

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

The present invention relates to a drug for treating or preventing ALK fusion gene-positive cancer positive for FGFR1 expression and positive for FGF2 expression at baseline, the drug comprising a compound having ALK inhibitory activity and a FGFR inhibitor in combination, a combination agent, a pharmaceutical composition, a preparation, a treatment or prevention method, or a drug for suppressing acquisition of resistance, a method for selecting a patient, and the like.

The application discloses a kind of compound based on fatty acid, mitochondrial targeting, inducing cancer cell apoptosis and immunogenic death and preparation method and application thereof, belong to the field of medicinal chemistry and preparation.The structural formula of the drug precursor is as shown in formula (I) and / or (II).The series of compounds can form relatively stable self-assembly in aqueous solution, show high cytotoxicity which simple triphenylphosphine and fatty acid do not have, and induce obvious ICD phenomenon of tumor cells.The drug can be obtained by simple synthesis, with high yield, low preparation cost, high stability, good safety, meet the requirements of clinical medication, meet the requirements of large-scale industrial production, have good market prospect and clinical application value.

This specification provides compounds having formula A, having an amide-based skeleton linked to multiple ring structures, pharmaceutically acceptable salts of these compounds, pharmaceutical compositions thereof, and the use of these compounds in medical therapeutic methods for the treatment of cancer as selective allosteric inhibitors of EGFR mutants, wherein the cancer is, for example, lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, non-small cell lung cancer (NSCLC), or cancer with brain metastases, wherein the cancer has at least one EGFR mutation selected from L858R, T790M, and C797S. [Formula 1] TIFF2026519479000418.tif27161

The present invention relates to a method for treating an eye disease in a subject in need of such treatment. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a 1-diisopropylphosphinoylalkane (DIPA) compound. The DIPA compound is a compound selected from DIPA-1-7, DIPA-1-8, and DIPA-1-9. The eye disease includes blepharitis and conjunctivitis.

The present invention relates to purpurin analogs and pharmaceutically acceptable salts thereof, and to compositions comprising purpurin analogs and pharmaceutically acceptable salts thereof. Purpurin analogs and pharmaceutically acceptable salts thereof are suitable for use, for example, in photodynamic therapy, cell luminescence therapy and photodynamic diagnostics for the treatment or detection of tumors or for antiviral treatment. The present invention also relates to the use of purpurin analogs and pharmaceutically acceptable salts thereof in the manufacture of phototherapy agents or photodiagnostic agents, and to methods for photodynamic therapy, cell luminescence therapy or photodynamic diagnostics for, for example, in the treatment or detection of tumors or for antiviral treatment. [Formula 1] JPEG2026519098000056.jpg66162

The present invention relates to mitochondrial-targeted agents and their utility in increasing telomere length and / or suppressing telomere shortening.

To provide compounds, compositions and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.SOLUTION: The invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, N-oxide, stereoisomer or isotopically enriched variant thereof.SELECTED DRAWING: None

A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having different water solubility embedded therewithin; and use thereof such as for the treatment of a disease is provided.

The present disclosure provides a method of inhibiting proliferation of a parasite or treating a disease caused by a parasite in a subject by administration of a mitochondria-targeted drug. Nonlimiting examples of the parasites include Brugia malayi and Dirofilaria immitis. Advantageously, movement of both male and female microfilaria can be inhibited by the mitochondria-targeted drug.

This invention provides methods and compositions for cancer immunotherapy. In various embodiments, the composition comprises functionally enhanced derived effector cells obtained by directed differentiation of genome-engineered iPSCs. In various embodiments, the derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Therapeutic compositions and their uses are also provided, comprising these functionally enhanced derived effector cells alone or in combination therapies.

This invention relates to reconstituted high-density lipoprotein nanoparticles containing cholesterol, and compositions containing the same for the prevention or treatment of Alzheimer's disease and cancer. Specifically, the reconstituted high-density lipoprotein nanoparticles containing cholesterol of this invention have an excellent intracellular uptake rate and a cancer cell death effect by promoting cholesterol efflux from cells, and can therefore be used for the prevention or treatment of cancer.

The present invention provides a method for treating and / or ameliorating a disorder of the lower urinary tract, comprising administering a composition comprising a glucagon like peptide 2 (GLP-2) receptor agonist to a patient in need thereof in an amount sufficient to treat and / or ameliorate the disorder of the lower urinary tract.

The present invention pertains to methods of using certain 1-di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) for the treatment of ocular discomfort that is caused by eye strain; eye surgery; an airborne irritant or pollutant that interacts with the eye surface; heat discomfort; extended wear of contact lenses; excessive exposure to the sun; asthenopia; conjunctivitis; or a dry eye syndrome. The present invention also pertains to pharmaceutical compositions comprising such compounds, and media contain those pharmaceutical compositions.

The present invention relates to a S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis and, more particularly, to a pharmaceutical composition and a health functional food composition, both comprising a sphingolipid compound which serves as a functional inhibitor against S1PR4, showing prophylaxis and therapy of non-alcoholic steatohepatitis. The sphingolipid compound of the present invention is expected to be applied as a leading material effective for the prevention or treatment of non-alcoholic steatohepatitis (NASH) as it has the effect of reducing the infiltration of inflammatory cells into hepatic tissues and suppressing fibrosis and decreases a level of liver injury (ALT), inflammation in hepatic tissues, the expression of a fibrosis-related gene.

This application pertains to a compound of Formula (I), Formula (I'), Formula (I") or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X, R1, R2, R3, R5, R6, and R7 are as defined herein, and uses of such compounds in methods of treating neurodegenerative diseases, neurodevelopmental disorders, and age-related memory impairment.

The present invention relates to polycyclic compounds and their uses.Specifically, the compounds of the present invention have the structure shown in formula I, wherein the definitions of each group and substituent are as described herein, and the present invention further discloses the preparation method of said compounds and their use in regulating and treating the related diseases caused by the abnormal activity of YAP / TEAD. [Formula 1] JPEG2024530956000247.jpg2362

Provided is a method for preventing or treating hearing loss in a subject in need thereof. The method includes administering to the subject an effective amount of inositol hexaphosphate or a salt or derivative thereof, fucoxanthin or a derivative thereof, or a combination thereof. Also provided is a composition for use in preventing or treating hearing loss in a subject in need thereof.

The present disclosure relates to STING agonists, pharmaceutical compositions thereof, and the use of agonists and pharmaceutical compositions for inducing STING-mediated immune responses and / or treating STING-mediated diseases and disorders, such as, but not limited to, proliferative diseases including cancer.

An anti-allergic product comprising a plant extract in an amount of at least 0.01% w / w, wherein the plant extract is selected from the group consisting of Camellia sinensis leaf extract, Melaleuca alternifolia leaf oil, and mixtures thereof, an amphiphilic preservative, and a glycolipid. The eyelid cleansing composition is configured to reduce redness, discomfort, and irritation in and around the eyelids.

The present invention relates to methods for treating endometriosis or preventing recurrence of endometriosis. In particular, the present invention relates to methods for treating endometriosis and recurrence thereof comprising administering to a female having endometriosis a pharmaceutical composition comprising an S-alkylisothiouronium derivative, specifically S-ethylisothiouronium diethylphosphate. The methods and pharmaceutical composition of the present invention preserve fertility and enable conception.

The present invention relates to a drug for treating or preventing ALK fusion gene-positive cancer positive for FGFR1 expression and positive for FGF2 expression at baseline, the drug comprising a compound having ALK inhibitory activity and a FGFR inhibitor in combination, a combination agent, a pharmaceutical composition, a preparation, a treatment or prevention method, or a drug for suppressing acquisition of resistance, a method for selecting a patient, and the like.